Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Share-based Compensation (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Share-based Compensation for 16 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 89.66% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.8 million through Dec 2025, up 14.02% year-over-year, with the annual reading at $46.8 million for FY2025, 14.02% up from the prior year.
  • Share-based Compensation hit $14.3 million in Q4 2025 for Ligand Pharmaceuticals, down from $14.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $29.1 million in Q4 2022 to a low of $5.7 million in Q4 2023.
  • Historically, Share-based Compensation has averaged $10.6 million across 5 years, with a median of $9.6 million in 2021.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 180.02% in 2022 and later tumbled 80.37% in 2023.
  • Year by year, Share-based Compensation stood at $10.4 million in 2021, then skyrocketed by 180.02% to $29.1 million in 2022, then crashed by 80.37% to $5.7 million in 2023, then soared by 31.52% to $7.5 million in 2024, then surged by 89.66% to $14.3 million in 2025.
  • Business Quant data shows Share-based Compensation for LGNDZ at $14.3 million in Q4 2025, $14.7 million in Q3 2025, and $10.0 million in Q2 2025.